We are live on ! Find out more
OGEN icon

Oragenics
OGEN

14 hedge funds and large institutions have $4.58M invested in Oragenics in 2017 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

74% more capital inflows, than outflows

Capital inflows: $44K | Capital outflows: $25.3K

27% more funds holding

Funds holding: 11 → 14 (+3)

0.13% more ownership

Funds ownership: 39.42% → 39.55% (+0.13%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
14
Holders Change
+3
Holders Change %
+27.27%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
4
Increased
1
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$12.6K
2
Virtu Financial
Virtu Financial
New York
+$12.6K
3
Deutsche Bank
Deutsche Bank
Germany
+$6.29K
4
Renaissance Technologies
Renaissance Technologies
New York
+$6.29K
5
UBS Group
UBS Group
Switzerland
+$6.29K

Top Sellers

Rank Fund Capital Flow
1
Bridgeway Capital Management
Bridgeway Capital Management
Texas
-$19K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$6.29K

OGEN Hedge Fund Activity: Q4 2017 in Review

14 of the 4,420 institutional investors tracked by Wall St. Rank reported a position in Oragenics (OGEN) for Q4 2017, worth a combined $4.58M — down 44% from $8.16M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new OGEN positions and 1 closed out — a net gain of 3 holders — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $12.6K. The largest seller was Bridgeway Capital Management, exiting entirely with an estimated $19K sold.

  • 14 institutional investors held Oragenics (OGEN) as of Q4 2017, up from 11 in Q3 2017.
  • Funds reported $4.58M of Oragenics stock for Q4 2017, down 44% quarter-over-quarter.
  • 4 funds opened new Oragenics positions in Q4 2017 and 1 closed out, a net change of +3 holders.
  • The largest Oragenics buyer in Q4 2017 was Citadel Advisors, an estimated $12.6K added.
  • The largest Oragenics seller in Q4 2017 was Bridgeway Capital Management, an estimated $19K sold.

Based on aggregated 13F filings for Q4 2017.